The Valeant stock price tanked 7% Monday and fell further today as things keep getting worse for the embattled drug company.
We called the Valeant stock price plunge last summer and remain bearish on the VRX stock price in 2016.
Here's what caused the latest rout, which backs our cautious stance...
The VRX stock price soared 15% to $29.91 today after the embattled drug company said no additional restatements are necessary after an internal audit.
The company now is facing anxious creditors of its $11 billion secured loans.
Valeant's woes are far from over...
The VRX stock price has plummeted 82% in the last six months because of predatory business practices.
Money Morning has covered the fall of Valeant Pharmaceuticals since October 2015, and our readers have made a profit of 700%.
It has been an incredibly volatile day for the Valeant stock price. VRX stock jumped more than 15% to $31.59 this morning (Monday) after the pharmaceutical giant announced sweeping changes to its board.
Valeant Pharmaceutics Internationa Inc. (NYSE: VRX) shares were briefly halted after the news broke. When trading resumed, Valeant stock plunged. Ten minutes into today's session, the Valeant stock price was down 1% to a new 52-week low of $26.
Here's what is next for Valeant stock in 2016...
The Valeant stock price has crashed 88% over the last six months, and the stock shows no sign of recovering.
And while many investors were crushed by the loss -- including famed activist Bill Ackman, who reportedly lost $1 billion on the stock - our readers made a profit of 700%.
Valeant not only missed expectations in its Q4 2015 earnings report, but also provided a bleak outlook for 2016.
The drug maker has dealt with countless scandals over the past six months, which has made the Valeant stock price plunge over 78% from its 52-week high of $263.81.
The Valeant stock price is in free fall. Valeant stock tumbled another 8% to $59.88 today (Tuesday) after crashing 18% Monday following reports that the beleaguered company is under investigation by the U.S. Securities and Exchange Commission (SEC).
Things are moving fast in the markets. If you pay attention, you could earn big profits from the unwinding of the biggest debt bubble in history.
Glencore and Valeant Pharmaceuticals present two such profit opportunities. They're both coming apart at the seams, and you're going to want to act quickly to profit from their problems.
Here's how to play Glencore and Valeant stock in 2016...
The VRX stock price saw one of its worst single-day performances of the year yesterday.
Shares plunged after CEO J. Michael Pearson took a medical leave of absence due to pneumonia.
Now investors are wondering if the stock is bottoming out and ready to move higher in 2016...
The Valeant Pharmaceutical International Inc. (NYSE: VRX) stock price has come under pressure yet again this week following a new downgrade and significantly lowered company guidance.
Late last week, Valeant lowered its Q4 outlook and guided Q1 fiscal 2016 sales and earnings below Wall Street estimates.
Here's why we see the VRX stock price drop continuing into 2016...
The Valeant Pharmaceuticals Inc. (NYSE: VRX) stock price soared some 16% to $110.98 Tuesday, but we remain bearish on the embattled drug maker in 2016.
You see, the company still faces a number of high hurdles.
Here's what you need to know...
There's been a ton of online chatter claiming that Valeant stock has become a screaming bargain.
And sure, it sounds like a bottom-feeder's dream come true. Since its Aug. 5 high, Valeant stock has dropped more than 65%. If it regained just 69% of its previous high, it would double.
But don't believe the hype. This is a deeply troubled company you should stay well away from.
Let me show you why you'll be glad you avoided this company at all costs...
The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price has dropped 44% year to date and nearly 80% over the last three months.
While some are saying VRX stock has now become undervalued, Money Morning Global Credit Strategist Michael Lewitt says the Valeant stock price will only continue to fall.
Here are this week's need-to-know facts about the stock market, economy, Wall Street, and life-changing global events...
It's the numbers that count in this crazy world. They can tell stories that words sometimes can't.
Valeant Pharmaceuticals (NYSE: VRX) has thrown in the towel on its questionable relationship with Philidor. Unfortunately, this move comes too late to save the reputation of VRX's management.
Here's a specific trade recommendation to bet against the rotten company.
It's a really good one for you that I think could bring a huge return - fast.
